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ABSTRACT 
 
FXII is considered a potential prothrombotic, proinflammatory and profibrinolytic protease. Evidence supports 
the concept that women with reduced plasma FXII level may be at high risk of developing premature delivery. 
FXII C46T polymorphism influences venous thrombosis and puerperium in asymptomatic women with no 
history of miscarriages. The prevalence of preeclampsia in obese women is high. The aim of this study was to 
examine whether there would be a correlation between the factor XII and dietary fatty acid. Immunochemical 
methods and functional techniques using a chromogenic peptide substrate assay were used. Although our 
findings were inconclusive, further research is needed.  
 
 
INTRODUCTION & BACKGROUND 
 
FXII (Hageman Factor) activates the 
plasma Kallikrein-Kinin System (KKS). This 
plasma protein is involved in the contact 
activation (intrinsic) pathway of blood 
coagulation. Activation of FXII to FXIIa 
begins the coagulation cascade, with the 
eventual formation of a fibrin clot. 
Circulating fatty acids have been proposed 
to provide a substrate for FXII activation1. 
Once activated, FXIIa, can catalyze 
Prekallikrein (PK) to kallikrein. Kallikrein then 
acts on High molecular weight Kininogen 
(HK) to generate Bradykinin (BK). Elevated 
BK has been shown to play a significant role 
in the pathogenesis of Hereditary 
Angioedema (HAE), and may be implicated 
in preeclamptic swelling. In the absence of 
the C1-inhibitor protein, there is 
uncontrolled generation of kallikrein and 
BK, which leads to severe edema in HAE 
patients. 
FXII is converted to FXIIa in an excess 
manner under pathophysiological 
conditions. FXIIa is significantly elevated in 
diseases such as non-alcoholic fatty liver 
disease2, diabetes mellitus, and diabetic 
retinopathy3. As these are diseases where 
fatty acids have been shown to be 
elevated4,5, our lab investigated the 
relationship between saturated, 
monounsaturated, and polyunsaturated fatty 
acids and FXII activation. Following 
experiments on fatty acids, we begun 
characterizing a new FXIIa inhibitor. Several 
hundred compounds from the National 
Center for Natural Products Research were 
screened in a double blind manner. Five 
compounds were found to inhibit FXIIa to 
various extents. Among these lead 
compounds, G1 avidly inhibited FXIIa. 
 
 
 
 
 
PURPOSE   
 
The goal of the current study is to 
determine the effects of fatty acids on 
plasma proteins, specifically FXII. 
Subsequently, the inhibitory characteristics 
of G1 were determined in order to 
understand how this compound interacts 
with different proteins. It is our hope that 
G1 will prove to be a selective inhibitor of 
FXIIa, and thus be a novel therapeutic for 
treating diseases such as Hereditary 
Angioedema.  
 
MATERIAL & METHODS 
 
Chromegenic FXIIa Activity Assay: The effect 
of fatty acids on the activity of FXIIa was 
quantified using a chromogenic assay. Effect 
of G1, a new inhibitor of plasma enzymes, was 
also characterized with the use of a 
chromogenic assay in the presence of 
kallikrein, FXIa, and FXIIa FXIIa (Enzyme 
Research Laboratories, South Bend, IN, USA) 
in fluid phase. The effect of fatty acids on 
FXIIa activity was determined using the 
chromogenic substrate CS-31(02) (Aniara  
 
 
Diagnostica, West Chester, OH, USA). In this 
experiment, 9 nM FXIIa was incubated with 
the chromogenic substrate CS-31(02). 
Subsequently, free para-nitroaniline was 
measured. Kallikrein (1 nM) and FXIa (18 nM) 
were measured in a similar manner, utilizing 
0.23 mM CS-31(02) and 0.43 mM S2366 
respectively. Plasma proteins were incubated 
with their respective enzyme in the absence or 
presence of increasing concentrations of fatty 
acids or potential inhibitory compound G1 
with a final volume of 100 µL HEPES-NaHCO3 
buffer (137 mM NaCl; 3 mM KCl; 14.7 mM 
HEPES; 1 mM MgCl2; 2 mM CaCl2; 5.5 mM 
glucose; and 0.1% gelatin, pH 7.1). For FXIa 
activity, (18 nM) FXIa (Enzyme Research 
Laboratories) was incubated with 0.43 mM 
S2366 (Glu-Pro-Arg-p-nitroanalide) in the 
absence or presence of the inhibitor. After 1 h 
of incubation at 37°C, the activity of kallikrein, 
FXIIa or FXIa was measured as a change in 
absorbance at OD 405 nm using BioTek 
ELx800 Absorbance Microplate Reader 
(Winooski, VT, USA). Data were analyzed 
using GraphPad Prism software (GraphPad 
Software, Inc., La Jolla, CA, USA). 
FIGURE 1. The Kallikrein-Kinin system can be activated 
locally and systemically by FXII. Feener, E. P., et. Al (2013). 
Thrombosis and Haemostasis, 110(3), 434-441. 
RESULTS 
 
Enzyme Kinetic Determination: Optimum concentrations of enzymes and substrates were 
determined. Once proper concentrations were specified, experimental time length was 
established through a time course.  
 
 
 
FIGURE 2. A) FXIIa activity was assayed to determine the optimal concentration of FXIIa in 
the presence of CS-31(02). Due to this experiment, 9 nM FXIIa was used in subsequent 
experiments to measure changes in FXIIa activity. B) The Km range obtained for CS-31(02) 
in the presence of FXIIa was 0.4375 to 0.5899 mM. For subsequent measurements of FXIIa 
activity, the final concentration of CS-31(02) equaled 0.43 mM. C) A time course using 9 nM 
FXIIa and 0.43 mM CS-31(02) was used to determine the ideal incubation time for the 
following experiments. Following this result, an incubation time of 1 hour was used for all 
experiments utilizing FXIIa, FXIa, and Kallikrein. 
 
 
FIGURE 3. Effect of fatty acid on FXIIa activity. Fatty acids were tested (replicates=3) to 
determine their effects on the catalytic activity of FXIIa. No fatty acids were found to show 
inhibition or stimulation of FXIIa. Data are presented as Mean ± SEM. 
	 
 
FIGURE 4. A) Determination of enzyme inhibition by compound G1. FXIIa and FXIa activity 
were reduced significantly by compound G1. However, G1 did not inhibit Kallikrein, which 
indicates its specificity for FXIIa and FXIa. B) G1 does not inhibit Kallikrein activity. Kallistop, 
a synthetic Kallikrein inhibitor was used to show that Kallikrein was not inhibited by G1. 
Data are presented as Mean ± SEM.  
	
DISCUSSION   
	
Substrate hydrolysis occurred in a time and 
concentration dependent manner. Fatty 
acids were not found to modulate the 
activity of FXIIa. G1 was found to inhibit 
coagulation factors XIIa and XIa, but not 
kallikrein. Further experiments are needed 
to determine fatty acid modulation of FXIIa, 
along with the effects of G1 on downstream 
components of the blood coagulation 
pathway and the Kallikrein-Kinin System. 
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